Decisions 16th May 2017


At the meeting that took place on 16th May, the following decisions were agreed.

New Drug Requests

Approved

Methenamine (TLS blue)

  • Approved for inclusion onto the formulary for UTI prophylaxis in patients for whom prophylaxis with trimethoprim or nitrofurantoin are unsuitable (due to allergy, resistance or insufficient renal function for nitrofurantoin) For use in moderate to severe renal impairment (10-45ml/min)

Symbicort pMDI (TLS green)

  • Approved for inclusion onto the formulary for COPD.

Ivermectin cream (TLS blue)

  • Approved for inclusion onto the formulary for patients with moderate to severe erythematotelanectatic, papular, pustular rosacea.

Moxifloxacin eye drops (TLS red)

  • Approved for inclusion onto the formulary for patients with microbial keratitis in which first line therapy with levofloxacin has failed.

Shared Care Protocols/TLS change in status

Tresiba (Insulin Degludec) (TLS amber)

  • Type 1 diabetes with recurrent severe hypoglycaemia, who have trialled avaliable long acting analogues but are unable to achieve target HbA1c and/or nocturnal hypoglycaemia remains a problem before starting insulin pump therapy
  • SCP approved

Other items

Glucodrate (TLS blue)

  • Licensed oral rehydration product now available so added to the formulary to replace unlicensed electrolyte products for short bowel syndrome.

QTERN (Saxagliptin/dapagliflozin) (TLS blue)

  • Added to the formulary. Constituent drugs already included on formulary.

Last updated by: Emily Knight on 09-10-2017 13:35